Royalty Pharma/$RPRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Royalty Pharma
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Ticker
$RPRX
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
-
Website
Royalty Pharma Metrics
BasicAdvanced
$16B
15.14
$2.45
0.48
$0.86
2.37%
Price and volume
Market cap
$16B
Beta
0.48
52-week high
$37.57
52-week low
$24.05
Average daily volume
3.4M
Dividend rate
$0.86
Financial strength
Current ratio
1.558
Quick ratio
1.556
Long term debt to equity
67.618
Total debt to equity
77.819
Dividend payout ratio (TTM)
34.59%
Interest coverage (TTM)
7.71%
Profitability
Gross margin (TTM)
99.06%
Net profit margin (TTM)
48.25%
Operating margin (TTM)
84.00%
Management effectiveness
Return on assets (TTM)
7.04%
Return on equity (TTM)
18.00%
Valuation
Price to earnings (TTM)
15.141
Price to revenue (TTM)
7.295
Price to book
2.36
Price to tangible book (TTM)
2.36
Price to free cash flow (TTM)
59.034
Free cash flow yield (TTM)
1.69%
Free cash flow per share (TTM)
0.629
Dividend yield (TTM)
2.32%
Forward dividend yield
2.37%
Growth
Revenue change (TTM)
1.13%
Earnings per share change (TTM)
37.69%
3-year revenue growth (CAGR)
-0.22%
3-year earnings per share growth (CAGR)
21.48%
3-year dividend per share growth (CAGR)
6.69%
What the Analysts think about Royalty Pharma
Analyst ratings (Buy, Hold, Sell) for Royalty Pharma stock.
Bulls say / Bears say
Royalty Pharma's recent $2 billion funding agreement with Revolution Medicines, including a $1.25 billion synthetic royalty on daraxonrasib and a $750 million secured loan, positions the company to benefit from potential future revenues of this promising therapy. (royaltypharma.com)
The acquisition of its external manager, RP Management, is expected to generate significant cash savings exceeding $100 million in 2026 and $175 million in 2030, enhancing shareholder value. (globenewswire.com)
Royalty Pharma's strong financial performance in Q3 2024, marked by a 15% growth in both Portfolio and Royalty Receipts totaling $735 million, reflects its robust business model and potential for sustained growth. (tipranks.com)
Royalty Pharma's Q4 2024 revenue of $594 million missed analyst estimates of $605.4 million, indicating potential challenges in meeting market expectations. (stockstory.com)
The company's operating margin declined to 60.9% in Q4 2024 from 103% in the same quarter the previous year, suggesting increased operational costs or reduced efficiency. (stockstory.com)
Despite a consensus 'Buy' rating, Citigroup reduced its target price for Royalty Pharma from $60.00 to $40.00, reflecting tempered expectations for the company's stock performance. (techdows.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Royalty Pharma Financial Performance
Revenues and expenses
Royalty Pharma Earnings Performance
Company profitability
Royalty Pharma News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Aug15
Royalty Pharma
Dividend·Ex-dividend
Sept10
Royalty Pharma
Dividend·Payment
$0.22Per share
FAQs
What’s the current market cap for Royalty Pharma stock?
Royalty Pharma (RPRX) has a market cap of $16B as of August 01, 2025.
What is the P/E ratio for Royalty Pharma stock?
The price to earnings (P/E) ratio for Royalty Pharma (RPRX) stock is 15.14 as of August 01, 2025.
Does Royalty Pharma stock pay dividends?
Yes, the Royalty Pharma (RPRX) stock pays dividends to shareholders. As of August 01, 2025, the dividend rate is $0.86 and the yield is 2.37%. Royalty Pharma has a payout ratio of 34.59% on a trailing twelve-month basis.
When is the next Royalty Pharma dividend payment date?
The next Royalty Pharma (RPRX) dividend payment is scheduled for September 10, 2025.
What is the beta indicator for Royalty Pharma?
Royalty Pharma (RPRX) has a beta rating of 0.48. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.